High Court concludes that methods of medical treatment are patentable
On 4 December 2013, the High Court judgment in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd & ors  HCA 50 was delivered. This is the first occasion that the High Court has considered whether methods of medical treatment of the human body are patentable inventions within the meaning of section 18(1) of the Patents Act 1990 (cth). The majority of the High Court concluded they were, while providing important guidance on contributory (or indirect) infringement in the context of patents which claim methods of medical treatment.
By way of background, the patent in issue was Australian Patent No 670491, entitled ’Pharmaceutical for the treatment of skin disorders’. Relevantly, the patent claims: ‘[a] method of preventing or treating a skin disorder wherein the skin disorder is psoriasis, which comprises administering to a recipient an effective amount of [leflunomide].’ Sanofi-Aventis Australia Pty Ltd (Sanofi) markets leflunomide in Australia under the brand name ARAVA.
In 2008, Apotex Pty Ltd (Apotex) obtained registrations for a generic leflunomide product. Shortly thereafter, Sanofi commenced infringement proceedings largely relying on section 117 of the Patents Act 1990 (Cth) which relates to contributory (or indirect) infringement…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
The land and buildings transaction tax will replace stamp duty land tax in Scotland on 1 April 2015.
The government has released an exposure draft of the Exploration Development Incentive (EDI) legislation.
Analysis from The Lawyer
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.